ºÚÁÏÍø

Overview

Number of students per year
10-12
Typical offer

The minimum offer is A*A*A at A-level or 7 7 6 (42+ overall) from Higher Level subjects in the IB or the equivalent. Applicants will also need to take the UCAT. 

 

Essential subjects

A-level/IB Higher Level or equivalent in Chemistry, and two of Biology, Physics, Mathematics, and Further Mathematics.

Useful subjects

Biology, Physics, Mathematics. 

IB applicants are expected to take IB Higher Level 'Analysis and Approaches' if available at your school. If this is not an option for you, email admissions@clare.cam.ac.uk and we will advise you.

​

Medicine at ºÚÁÏÍø

The Cambridge course differs sharply from that of most other medical schools. The aim is not only to train students in medicine to the highest standards, but also to have the skills needed to improve patient treatment through research.

The first two years of the course provide comprehensive training in the sciences that underpins clinical medicine. All students attend weekly tutorials in each subject. These last an hour and are an opportunity for groups of 3-4 students to discuss their questions with expert supervisors, most of whom are clinicians who can bring the course alive by showing how it connects with treating patients. 

In the third year students can choose to study one of a wide range of subjects in depth. This gives everyone the opportunity to develop skills in evaluating evidence and rigorously testing hypotheses essential for discovering how to improve patient care.

The final three years of the course are spent at Addenbrooke's Hospital, a leading teaching hospital at the forefront of medical care internationally.

Our ºÚÁÏÍø students come from a diverse range of backgrounds. ºÚÁÏÍø medics are friendly and supportive, and there is a lively student run Medical Society that brings together medics from all 6 years of the course.

ºÚÁÏÍø has excellent facilities to support medics in their studies. Recent student achievements include the foundation of the and .

Visit the University's  for more information.

 

David Rowitch image

Professor Rowitch is a developmental neuroscientist and Head of Department of Paediatrics at University of Cambridge. His laboratory investigates genetic factors that determine development and diversity of glial cells of the brain and the response to injury. He has applied these principles to better understand white matter injury in premature infants, brain cancer and leukodystrophy. His interest in precision medicine focuses on applications of genomic technologies to diagnose and better understand the biological basis and rational treatment of rare neurological disorders.

David Rowitch
Director of Studies in Medicine
Dr Qi Guo

Dr Guo works in the fields of genetic epidemiology, biostatistics, and machine learning. Her research focuses on exploring interdisciplinary approaches to gain deeper insights into human biology. Her interests include applying genetics and computational methods to solve complex biological problems and advance fields such as healthcare and personalised medicine. 

Qi Guo
College Research Associate
ºÚÁÏÍø

Dr Arora is a Consultant Paediatrician at Addenbrooke's Hospital and Lead for Student Experience at the Clinical School. She is Assistant Director of Clinical Studies for Medicine at ºÚÁÏÍø.

Michelle Arora
Director of Studies in Clinical Medicine
Paul Fletcher image

I am a psychiatrist interested in how the brain builds up an image of the world in which it must survive. Many of us think that we see the world as it is: we don’t. I like to use brain imaging to understand how the brain goes about its deceitful business. I also give drugs to people. These drugs alter their perceptions of the world and help me to understand how the early symptoms of mental illness might arise. I don’t require my students to act as volunteers for these studies.

Paul Fletcher
Director of Studies in Pre-Clinical Medicine
ºÚÁÏÍø

I work as a clinical doctor, treating patients with skin cancer and also as a scientist researching how normal cells change as they turn into cancer.

Our research has shown that cells with DNA alterations linked to cancer spread through normal tissues, so that by middle age most of our cells carry at least one cancer linked DNA change. This process works like Darwinian evolution, with environmental selection of specific alterations in cells that improve their competitive fitness.

We hope that by changing the environment we will be able to redirect evolution so pre-cancerous cells in normal tissues are selected out and the risks of cancer reduced.

Philip Jones
Director of Studies in Pre-Clinical Medicine